Since immunotherapy activates the immune system, and ICAM-1 blockade diminishes tumor retention and improves lymphocyte recirculation, patients with metastasis, multiple or recurrent lesions could benefit from this combination. The gene discussed is ICAM1; the disease is neoplasm.